Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary Optival Health Solutions Private Limited received a 7-day suspension order for the drug license of a store located in Shahu Nagar, Karnataka. The order was issued on April 18, 2025 by the Assistant Director, Drugs Control Administration, Bangalore Circle-Belagavi, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has estimated the potential revenue loss from this suspension at approximately Rs 1.36 lakhs. The disclosure is filed under SEBI's Regulation 30 listing obligations.
The financial impact is negligible at around Rs 1.36 lakhs for a single store over a 7-day period and is unlikely to materially affect the company's overall operations or stock price. This appears to be a routine regulatory compliance update.